Evidence map›Paper›PMID 34707756›Full record

ArticleThe Pan African medical journal2021

SARS-CoV-2 in Zimbabwe: milestones and challenges faced towards achieving the expected 60% herd immunity.

Vinie Kouamou, Richard Matarise, Elizabeth Dos Santos, Nyasha Elose, Justen Manasa

Abstract read
In one paragraph

Article in The Pan African medical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Vinie KouamouFaculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Richard MatariseFaculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Elizabeth Dos SantosFaculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Nyasha EloseFaculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Justen ManasaFaculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In response to COVID-19 pandemic, the Zimbabwe government put in place various rigorous measures to curb the spread of the virus. Although roll-out and access to COVID-19 vaccines in Africa have been slow, the World Health Organization (WHO)-led COVID-19 Vaccines Global Access (COVAX) consortium and the African vaccine acquisition task team are striving to provide 720 million doses of COVID-19 vaccines to achieve 60% coverage in Africa by June, 2022. In line with this, the Zimbabwe vaccination programme commenced on the 26

Indexed as

COVID-19 VaccinesImmunity, HerdCOVID-19HumansPandemicsSARS-CoV-2ZimbabweCOVID-19 VaccinesCOVID-19VaccineZimbabwe

Identifiers

PMID34707756
PMCPMC8520422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.